Recombinant bacillus Calmette-Guerin in urothelial bladder cancer immunotherapy: current strategies

被引：8
|
作者：
Wang, Yonghua [1 ]
Yang, Meng [1 ]
Yu, Qinchao [1 ]
Yu, Lun [1 ]
Shao, Shixiu [1 ]
Wang, Xinsheng [1 ]
机构：
[1] Qingdao Univ, Affiliated Hosp, Dept Urol, Qingdao 266071, Peoples R China
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2015年 / 15卷 / 01期
基金：
中国国家自然科学基金;
关键词：
bacillus Calmette-Guerin; BCG; immunotherapy; intravesical therapy; recombinant BCG; urothelial bladder cancer; TRANSITIONAL-CELL CARCINOMA; EXPRESSING PERTUSSIS TOXIN; GAMMA-INDUCING FACTOR; MYCOBACTERIUM-BOVIS; IFN-GAMMA; INTRAVESICAL THERAPY; DNA VACCINES; MITOMYCIN-C; TH1-STIMULATING CYTOKINES; PLUS INTERFERON-ALPHA-2B;
D O I：
10.1586/14737140.2015.961430
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Bacillus Calmette-Guerin (BCG) has been used in the intravesical treatment of urothelial bladder cancer (UBC) for three decades. Despite its efficacy, intravesical BCG therapy is associated with some limitations such as side effects and BCG failure, which have inspired multiple ways to improve it. Recent advances have focused on recombinant BCG (rBCG) which provides a novel tactic for modification of BCG. To date, a number of rBCG strains have been developed and demonstrated to encourage efficacy and safety in preclinical and clinical studies. This review summarizes current rBCG strategies, concerns and future directions in UBC immunotherapy with an intention to encourage further research and eventually to inform clinical decisions.
引用
收藏
页码：85 / 93
页数：9
相关论文
共 50 条
  • [21] Bacillus of Calmette-Guerin immunotherapy: which protocol?
    Saint, Fabien
    PROGRES EN UROLOGIE, 2008, 18 : S99 - S104
  • [22] History of bacillus Calmette-Guerin and bladder cancer: An immunotherapy success story
    Herr, Harry W.
    Moralest, Alvaro
    JOURNAL OF UROLOGY, 2008, 179 (01) : 53 - 56
  • [23] INTRAVESICAL CHEMOTHERAPY (MITOMYCIN-C) VERSUS IMMUNOTHERAPY (BACILLUS CALMETTE-GUERIN) IN SUPERFICIAL BLADDER-CANCER
    RINTALA, E
    JAUHIAINEN, K
    ALFTHAN, O
    HANSSON, E
    JUUSELA, H
    KANERVA, K
    KORHONEN, H
    PERMI, J
    SOTARAUTA, M
    VAALASTI, T
    VIITANEN, J
    USENIUS, R
    EUROPEAN UROLOGY, 1991, 20 (01) : 19 - 25
  • [24] Bacillus Calmette-Guerin strain differences as the basis for immunotherapies against bladder cancer
    Miyazaki, Jun
    Onozawa, Mizuki
    Takaoka, Eiichiro
    Yano, Ikuya
    INTERNATIONAL JOURNAL OF UROLOGY, 2018, 25 (05) : 405 - 413
  • [25] The bacillus Calmette-Guerin as immunomodulator in bladder cancer
    Gabriel Vazquez-Lavista, Luis
    Haydee Flores-Balcazar, Christian
    Llorente, Luis
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2007, 59 (02): : 146 - 152
  • [26] Current status of tuberculosis and recombinant bacillus Calmette-Guerin vaccines
    Ohara, Naoya
    JOURNAL OF ORAL BIOSCIENCES, 2012, 54 (02): : 92 - 95
  • [27] Predictive biomarkers of response to bacillus Calmette-Guerin immunotherapy and bacillus Calmette-Guerin failure for non-muscle invasive bladder cancer
    Wang, Ziting
    So, Wei Zheng
    Loh, Kep Yong
    Lim, Yew Koon
    Mahendran, Ratha
    Wu, Qing Hui
    Chiong, Edmund
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 (08) : 807 - 815
  • [28] Intravesical bacillus Calmette-Guerin for bladder cancer: are all the strains equal?
    D'Andrea, David
    Gontero, Paolo
    Shariat, Shahrokh F.
    Soria, Francesco
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2019, 8 (01) : 85 - 93
  • [29] What to do during Bacillus Calmette-Guerin shortage? Valid strategies based on evidence
    Abufaraj, Mohammad
    Mostafid, Hugh
    Shariat, Shahrokh F.
    Babjuk, Marek
    CURRENT OPINION IN UROLOGY, 2018, 28 (06) : 570 - 576
  • [30] Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine
    Lee, CF
    Chang, SY
    Hsieh, DS
    Yu, DS
    JOURNAL OF UROLOGY, 2004, 171 (03) : 1343 - 1347
12345